-
Company Insights
Innovation and Patenting activity of Suven Pharmaceuticals Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Suven Pharmaceuticals Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Ovarian Cancer Drug Details: Defactinib hydrochloride (VS-6063)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masupirdine in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masupirdine in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masupirdine in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
Narcolepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Narcolepsy - Drugs In Development, 2023’, provides an overview of the Narcolepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cognitive Impairment Associated With Schizophrenia (CIAS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Drugs In Development, 2023’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...